21/07/2009
ReGen Therapeutics Plc (AIM:RGT) are pleased to announce that at the Annual General Meeting held today, all resolutions were passed.
The Chairman highlighted a number of positive developments:
- Our Cypriot partner Golgi has now put Cognase™ on daily dosing. This less complicated regimen we believe will further aid sales development in Cyprus and the other South Eastern European territories, which Golgi is developing.
- The Company has been successful in raising over £397,000 this year
- First commercial orders have been received from Tagerr for Poland and full scale commercial development is under way there.
- Our Turkish partner Eczacibasi has obtained import license approval from the Turkish Authorities to import and distribute Colostrinin™ as Dyna™. This is the first step in the approval process for Turkey.
- We are in detailed discussions with a global company on the further development of Colostrinin™ and derived peptides in obesity.
- We are investigating the possibility of marketing Colostrinin™ in the UK.
The Board expects sustainable profitability to be achieved in 2010 and its worldwide Colostrinin™ roll-out programme is proceeding successfully.
For further information please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David Securities Limited
Tel: 020 7448 9820